Guanfacine
- Generic Name
- Guanfacine
- Brand Names
- Intuniv, Tenex
- Drug Type
- Small Molecule
- Chemical Formula
- C9H9Cl2N3O
- CAS Number
- 29110-47-2
- Unique Ingredient Identifier
- 30OMY4G3MK
- Background
Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974.
Guanfacine was granted FDA approval on 27 October 1986.
- Indication
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Gilles de la Tourette's Syndrome, Hypertension, Migraine
Inuniv and Working Memory
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Lori A. Schweickert, MD
- Target Recruit Count
- 18
- Registration Number
- NCT01177306
- Locations
- 🇺🇸
3C Family Services, Cary, North Carolina, United States
Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
- Conditions
- Attention Deficit DisorderAttention-Deficit/Hyperactivity DisorderSleep DisordersInsomnia
- Interventions
- Drug: Placebo comparator
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Children's Specialized Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT01156051
- Locations
- 🇺🇸
Children's Specialized Hospital, Toms River, New Jersey, United States
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Neurology Group of Bergen County, P.A.
- Target Recruit Count
- 30
- Registration Number
- NCT01146002
- Locations
- 🇺🇸
Neurology Group of Bergen County, Ridgewood, New Jersey, United States
Interventions for Children With Attention and Reading Disorders
- Conditions
- Attention Deficit Hyperactivity DisorderReading Disabilities
- Interventions
- Behavioral: Intensive reading instructionBehavioral: Parent Training
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2017-04-11
- Target Recruit Count
- 222
- Registration Number
- NCT01133847
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Texas Health Science Center, Houston, Texas, United States
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention-deficit/Hyperactivity Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 528
- Registration Number
- NCT01081145
- Locations
- 🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Amedica Research Institute, Inc., Hialeah, Florida, United States
🇺🇸Ohio State University, Nisonger Center, Columbus, Ohio, United States
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Shire
- Target Recruit Count
- 314
- Registration Number
- NCT01081132
- Locations
- 🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Florida Clinical Research Center, LLC, Bradenton, Florida, United States
🇺🇸Clinical Neurophysiology Services, PC, Sterling Heights, Michigan, United States
Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2012-09-03
- Target Recruit Count
- 42
- Registration Number
- NCT01069523
- Locations
- 🇺🇸
Dept. Of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 340
- Registration Number
- NCT00997984
- Locations
- 🇺🇸
CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States
🇺🇸Vermont Clinical Study Center, Burlington, Vermont, United States
🇺🇸University of Illinois Chicago, Chicago, Illinois, United States
Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 13
- Registration Number
- NCT00955253
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 154
- Registration Number
- NCT00935493
- Locations
- 🇺🇸
Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.